• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

ECMO Breathing Support Safe, Effective for Obese Patients in Respiratory Failure

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

TUESDAY, Aug. 29, 2023 -- Using ECMO, a highly advanced form of breathing support, does not appear to complicate treatment for obese adults in intensive care.

ECMO, which is short for extracorporeal membrane oxygenation, may even help these patients when they experience respiratory failure, despite the fact that its use has been questioned for those with obesity.

Obese patients who received ECMO for acute respiratory distress syndrome (ARDS) had lower death rates compared to patients with ARDS who received ECMO and were not obese, according to the study funded by the U.S. National Institutes of Health (NIH).

To come to that conclusion, the researchers reviewed data from 790 patients from more than 20 medical centers across 10 countries who received ECMO for ARDS.

In all, 320 of these patients were obese. The study found 24% of patients with obesity died in the intensive care unit, compared to 35% of patients who weren't obese.

Although the authors couldn’t control for all variables, including disease severity, they concluded the findings support the concept that obesity shouldn’t factor into treatment decisions for ECMO.

“We hope that clinicians will consider the data from this study when making bedside decisions for ARDS patients with obesity, instead of preemptively withholding this lifesaving therapy,” study author Dr. Darya Rudym, a pulmonologist and assistant professor of medicine at NYU Langone Health in New York City, said in an NIH news release.

That was in line with previous studies that have found similar findings looking at data from patient registries and observational reviews.

ARDS accounts for roughly 10% of intensive care unit admissions worldwide.

Pneumonia was the most common factor leading to the severe respiratory illness seen in this study.

Survival rates for ARDS vary, with about half to three-fourths of patients surviving. Survival rates for ECMO, which is considered a last-resort treatment, are also variable, but have ranged from about 60% to 75%.

The study, which was published recently in the American Journal of Respiratory and Critical Care Medicine, was partially supported by the U.S. National Heart, Lung, and Blood Institute (NHLBI) and the U.S. National Center for Advancing Translational Sciences.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.